-
July 11, 2024
The Personalized Power of the “N-of-1” Approach
With:Randomized, controlled clinical trials with a large N—number of participants—are the recognized “gold standard” of evidence-based medicine. Even so, the results of large-N trials can only reveal population averages, and are not predictive of any individual’s response to a given treatment. On the other hand, one can consider every patient with cancer as the sole participant in their own clinical trial with an Nof1, even if the trial is not… Read more »
-
November 10, 2022
A Powerful Knowledge Base for Precision Oncology
With:Genetic mutations found in a tumor can be important clues to the patient’s best treatment options. Memorial Sloan Kettering Cancer Center (MSK) in New York has developed a product called OncoKB™, which enables anyone to access and navigate key clinical information about the various genetic abnormalities that may be found in tumors. Here, Curious Dr. George asks MSK Lead Software Engineer Hongxin Zhang about… Read more »
-
June 2, 2022
Harnessing Each Patient’s Data to Help Many More
With: Kaumudi Bhawe, PhDAt Cancer Commons, we don’t just help people navigate cancer treatment; we learn from everyone we help. Here, our Curious Dr. George asks Cancer Commons Clinical Scientist Kaumudi Bhawe, PhD, to share how new knowledge can be captured from every patient to help many more. Curious Dr. George: Cancer Commons has accumulated in-depth data on many hundreds of patients with various cancers. Because of the… Read more »
-
May 23, 2022
Plain Language Summaries Improve Access to Medical Research
With:Cancer Commons helps people make sense of the latest research on treatments for their distinct type of cancer. Meanwhile, a growing number of research papers now include a plain language summary (PLS)—an overview of the paper written for anybody to understand. Here, our Curious Dr. George discusses plain language summaries with Adeline Rosenberg, MSc, Senior Medical Writer at the healthcare communications company Oxford PharmaGenesis,… Read more »
-
April 13, 2022
Cancer Commons Adapts to Remain True to Our Mission
With:People facing advanced cancer come to Cancer Commons to ensure they have all the information they need to make their best-possible cancer care decisions. Here, Curious Dr. George asks our CFO & COO Shelley Frisbie about recent updates to our organization. Curious Dr. George: You have been the CFO of Cancer Commons for some time and recently added the COO title and duties to… Read more »
-
March 16, 2022
Cellular Aging and the Development of Cancer
With: Kaumudi Bhawe, PhDCancer is so often a disease of older people that a whole medical field, “oncogeriatrics,” exists to address the topic. Deeper understanding of the links between cancer and aging could lead to better treatments. Here, our Curious Dr. George asks Cancer Commons Clinical Scientist Kaumudi Bhawe, PhD, about the relationship between cancer and aging processes that occur in individual cells in our bodies—throughout our… Read more »
-
March 8, 2022
National Colorectal Cancer Awareness Month Bookmark
George Lundberg, MDMarch 2022 is Colorectal Cancer Awareness Month in the U.S., as recognized by The White House.
.
-
February 18, 2022
DIPG All-In-Initiative Awards $35,000 Grant for Pediatric Brain Tumor Research Bookmark
George Lundberg, MDAs announced by Cancer Commons partner the Musella Foundation For Brain Tumor Research & Information, Inc., a collaboration of groups has announced funding to support research into possible treatments for pediatric diffuse intrinsic pontine glioma (DIPG).
.
-
February 3, 2022
World Cancer Day 2022 Bookmark
George Lundberg, MDIn 2000, the Union for International Cancer Control established World Cancer Day, to be held every year on February 4. This year’s theme is “Close the Care Gap,” which is “all about understanding and recognizing the inequities in cancer care around the globe.” Learn more here.
.
-
October 18, 2021
Running Virtual Trials with Self-Reported Brain Cancer Patient Data Bookmark
George Lundberg, MDThis scientific report from medRxiv demonstrates how self-reported data from brain cancer patients could be used to run “virtual trials” that complement traditional clinical trials by generating knowledge that could help inform precision cancer treatment.
.